Wyeth gets priority review for new version of Prevnar
Drug maker Wyeth said Thursday federal regulators have granted a priority review to a new version of its blockbuster infant vaccine Prevnar, and the company expects a regulatory decision within six months. Wyeth ( WYE – news – people ) submitted an application to the U.S. Food and Drug Administration on March 31. Prevnar, on the market [...] [...more]
